Medicure

                   

Medicure Repays $12 Million Senior Debt

marketwire.com
03-Nov-2008 1 related
        

UPDATES ON OUTCOME OF 2008 ANNUAL AND SPECIAL MEETING WINNIPEG, MANITOBA--(Marketwire - Medicure Inc. (TSX:MPH), a cardiovascular focused, biopharmaceutical company, today announced the repayment of US$12 million in senior...

add comment

Medicure to Report Second Quarter Fiscal 2008 Financial Results (Marketwire)

yahoo.com
27-Oct-2008
        

WINNIPEG, MANITOBA--(MARKET WIRE)--Jan 11, 2008 -- Medicure Inc. (Toronto: ), a cardiovascular focused biopharmaceutical company, today announced that the Company will report second quarter fiscal 2008 financial results on...

add comment
                   

Medicure Announces Second Quarter Fiscal 2008 Financial Results (Marketwire)

yahoo.com
27-Oct-2008
        

WINNIPEG, MANITOBA--(MARKET WIRE)--Jan 14, 2008 -- Medicure Inc. (Toronto: ), a cardiovascular focused biopharmaceutical company, today reported the results of operations for the three and six month periods ended November 30,...

add comment
                   

Medicure Announces Top-Line Results From Pivotal Phase 3 MEND-CABG II Clinical Trial (Marketwire)

yahoo.com
27-Oct-2008
        

Friday February 22, 2008 4:32 pm ET MEND-CABG II Study Does Not Meet Primary Efficacy Endpoint WINNIPEG, MANITOBA--(MARKET WIRE)--Feb 22, 2008 -- Medicure Inc. (Toronto: ), a cardiovascular-focused biopharmaceutical company,...

add comment

Medicure's Pivotal Phase 3 MEND-CABG II Results to be Presented at Late-Breaking Session at the...

yahoo.com
27-Oct-2008
        

Tuesday February 5, 2008 8:00 am ET WINNIPEG, MANITOBA--(MARKET WIRE)--Feb 5, 2008 -- Medicure, Inc. (Toronto: ), a cardiovascular-focused biopharmaceutical company, today announced that the results of the Company's pivotal...

add comment
                   

Medicure Announces Third Quarter Fiscal 2008 Financial Results (Marketwire)

yahoo.com
27-Oct-2008
        

WINNIPEG, MANITOBA--(MARKET WIRE)--Apr 14, 2008 -- Medicure Inc. (Toronto: ), a cardiovascular-focused biopharmaceutical company, today reported the results of operations for the three and nine month periods ended February 29,...

add comment